<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718079</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-ALF-03</org_study_id>
    <nct_id>NCT02718079</nct_id>
  </id_info>
  <brief_title>High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure</brief_title>
  <official_title>High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure-A Prospective Randomized Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted on patients admitted to Department of Hepatology from Jan 2016 to
      Jan 2018 at Institute of Liver &amp; Biliary Sciences, New Delhi. Study group will comprise of
      patients with acute liver failure (ALF) who have no option for liver transplant (due to any
      reason) or have contraindications for liver transplant or have no prospective living donor
      and will be assessed for enrollment in the trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 30, 2016</start_date>
  <completion_date type="Actual">October 18, 2018</completion_date>
  <primary_completion_date type="Actual">October 8, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival in both groups.</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Intensive Care Unit stay in both groups.</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in SIRS (Systemic Inflammatory Response Syndrome) score.</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in SIRS (Systemic Inflammatory Response Syndrome) score.</measure>
    <time_frame>day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in SIRS (Systemic Inflammatory Response Syndrome) score.</measure>
    <time_frame>day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in SOFA (Sequential Organ Failure Assessment) score.</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in SOFA (Sequential Organ Failure Assessment) score.</measure>
    <time_frame>day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in SOFA (Sequential Organ Failure Assessment) score.</measure>
    <time_frame>day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in APACHE II (Acute Physiology and Chronic Health Evaluation) score.</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in APACHE II (Acute Physiology and Chronic Health Evaluation) score.</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in APACHE II (Acute Physiology and Chronic Health Evaluation) score.</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on systemic haemodynamics in both groups.</measure>
    <time_frame>24 hours</time_frame>
    <description>Effect is defined as resolution of SIRS (Systemic Inflammatory Response Syndrome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on systemic haemodynamics in both groups.</measure>
    <time_frame>48 hours</time_frame>
    <description>Effect is defined as resolution of SIRS (Systemic Inflammatory Response Syndrome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pro inflammatory cytokines profile in both groups.</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Endotoxin levels in both groups.</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Acute Liver Failure</condition>
  <arm_group>
    <arm_group_label>Standard medical therapy with Plasma Exchange</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma Exchange will be performed for consecutive days. Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard medical therapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma Exchange</intervention_name>
    <arm_group_label>Standard medical therapy with Plasma Exchange</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Management of cerebral edema/intracranial hypertension:</intervention_name>
    <arm_group_label>Standard medical therapy alone</arm_group_label>
    <arm_group_label>Standard medical therapy with Plasma Exchange</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transfer to Intensive Care Unit</intervention_name>
    <arm_group_label>Standard medical therapy alone</arm_group_label>
    <arm_group_label>Standard medical therapy with Plasma Exchange</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prophylactic Antibiotics</intervention_name>
    <arm_group_label>Standard medical therapy alone</arm_group_label>
    <arm_group_label>Standard medical therapy with Plasma Exchange</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intubation of trachea</intervention_name>
    <arm_group_label>Standard medical therapy alone</arm_group_label>
    <arm_group_label>Standard medical therapy with Plasma Exchange</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure</intervention_name>
    <arm_group_label>Standard medical therapy alone</arm_group_label>
    <arm_group_label>Standard medical therapy with Plasma Exchange</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Volume Replacement</intervention_name>
    <arm_group_label>Standard medical therapy alone</arm_group_label>
    <arm_group_label>Standard medical therapy with Plasma Exchange</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pressor Support</intervention_name>
    <arm_group_label>Standard medical therapy alone</arm_group_label>
    <arm_group_label>Standard medical therapy with Plasma Exchange</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl-L-cysteine</intervention_name>
    <arm_group_label>Standard medical therapy alone</arm_group_label>
    <arm_group_label>Standard medical therapy with Plasma Exchange</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Correction of metabolic parameters</intervention_name>
    <arm_group_label>Standard medical therapy alone</arm_group_label>
    <arm_group_label>Standard medical therapy with Plasma Exchange</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Correction of nutrition</intervention_name>
    <arm_group_label>Standard medical therapy alone</arm_group_label>
    <arm_group_label>Standard medical therapy with Plasma Exchange</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute liver failure defined as : Patients with jaundice which is
             complicated by encephalopathy and coagulopathy within 4 weeks of the onset of jaundice
             and without underlying chronic liver disease.

        Exclusion Criteria:

          -  Age &lt;12 or &gt; 75 years

          -  Hepato-Cellular Carcinoma

          -  Active untreated Sepsis/DIC

          -  Any evidence of active bleed secondary to coagulopathy

          -  Hemodynamic instability requiring high dose of Vasopressors

          -  Coma of non-hepatic origin.

          -  Pregnancy

          -  Comorbidities associated with poor outcome (Extrahepatic neoplasia, severe
             cardiopulmonary disease defined by a New York Heart Association score &gt;3, or
             oxygen/steroid-dependent chronic obstructive pulmonary disease).

          -  Patients being taken up for liver transplant

          -  Refusal to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Rakhi Maiwall, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver and Biliary Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

